“Overview of the Safety Profile From Efgartigimod Clinical Trials in Participants With Diverse IgG-Mediated Autoimmune Diseases”. 2024. SKIN The Journal of Cutaneous Medicine 8 (1): s344. https://doi.org/10.25251/skin.8.supp.344.